Sat, May 18, 2024
Volume 9, Issue 4 (Autumn 2023)
Caspian J Neurol Sci 2023, 9(4): 229-243 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Soleimani R, Jalali M M, Bakhtiari H, Eslamdoust-Siahestalkhi F, Jalali S M. Probiotic Add-on Therapy in the First-episode Schizophrenia: A Randomized Controlled Trial. Caspian J Neurol Sci 2023; 9 (4) :229-243
URL: http://cjns.gums.ac.ir/article-1-665-en.html
URL: http://cjns.gums.ac.ir/article-1-665-en.html
Robabeh Soleimani * 
1, Mir Mohammad Jalali2 , Hoda Bakhtiari1 , Fatemeh Eslamdoust-Siahestalkhi1 , Seyede Melika Jalali3
1, Mir Mohammad Jalali2 , Hoda Bakhtiari1 , Fatemeh Eslamdoust-Siahestalkhi1 , Seyede Melika Jalali3
1- Department of Psychiatry, Kavosh Cognitive Behavior Sciences and Addiction Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
2- Department of Otolaryngology Head and Neck Surgery, Otorhinolaryngology Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
3- Department of Pharmacology, Faculty of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
2- Department of Otolaryngology Head and Neck Surgery, Otorhinolaryngology Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
3- Department of Pharmacology, Faculty of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
Abstract: (347 Views)
Background: Some evidence supports probiotics’ beneficial effects on clinical symptoms of patients
with schizophrenia and relieving unwanted frequently associated side effects of antipsychotic drugs
such as constipation, obesity, and metabolic disorders.
Objectives: This study aimed to assess the effect of probiotic supplements on clinical psychiatry
symptoms and metabolic indices in patients with schizophrenia.
Materials & Methods: First-episode schizophrenic patients were randomly assigned to probiotics
and placebo groups in a randomized controlled trial that took 12 weeks. The primary outcomes were
the brief psychiatric rating scale (BPRS) change scores and positive and negative syndrome scale
(PANSS). The secondary outcomes were clinical global impression-improvement scale (CGI-S),
blood pressure (BP), body mass index (BMI), lipid profiles, and fasting blood sugar (FBS).
Results: A total of 62 patients were considered for the intention-to-treat analysis (mean age, 34.7
years; 23 women; 39 men). The results showed no significant differences in the primary objectives
between the probiotic and placebo groups. In the probiotic group, subjects had lower levels of all
biochemical variables (triglycerides, cholesterol, and FBS) compared to the subjects in the placebo
group (standardized mean difference -4.3, -2.8, and -4.6, respectively; P<0.05).
Conclusion: We found that by adding probiotics to oral antipsychotics, BPRS or PANSS scores do not
improve. However, Cohen’s d for biochemical variables showed a medium to large effect size. This
study suggests probiotic supplementation may regulate and control triglycerides, cholesterol, and FBS
levels. Future studies are recommended to demonstrate these findings in the confirmatory analysis.
with schizophrenia and relieving unwanted frequently associated side effects of antipsychotic drugs
such as constipation, obesity, and metabolic disorders.
Objectives: This study aimed to assess the effect of probiotic supplements on clinical psychiatry
symptoms and metabolic indices in patients with schizophrenia.
Materials & Methods: First-episode schizophrenic patients were randomly assigned to probiotics
and placebo groups in a randomized controlled trial that took 12 weeks. The primary outcomes were
the brief psychiatric rating scale (BPRS) change scores and positive and negative syndrome scale
(PANSS). The secondary outcomes were clinical global impression-improvement scale (CGI-S),
blood pressure (BP), body mass index (BMI), lipid profiles, and fasting blood sugar (FBS).
Results: A total of 62 patients were considered for the intention-to-treat analysis (mean age, 34.7
years; 23 women; 39 men). The results showed no significant differences in the primary objectives
between the probiotic and placebo groups. In the probiotic group, subjects had lower levels of all
biochemical variables (triglycerides, cholesterol, and FBS) compared to the subjects in the placebo
group (standardized mean difference -4.3, -2.8, and -4.6, respectively; P<0.05).
Conclusion: We found that by adding probiotics to oral antipsychotics, BPRS or PANSS scores do not
improve. However, Cohen’s d for biochemical variables showed a medium to large effect size. This
study suggests probiotic supplementation may regulate and control triglycerides, cholesterol, and FBS
levels. Future studies are recommended to demonstrate these findings in the confirmatory analysis.
Type of Study: Research |
Subject:
Special
Received: 2023/10/11 | Accepted: 2023/10/17 | Published: 2023/10/17
Received: 2023/10/11 | Accepted: 2023/10/17 | Published: 2023/10/17
| Rights and permissions | |
 | This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Articles Copyright © The Author(s).
Owned by Guilan University of Medical Sciences.
Co-published by Negah Institute for Scientific Communication.
Contact Information
Caspian Journal of Neurological Sciences
Guilan University of Medical Sciences
University Tel : +9813 3333 0939
E-mail: cjnsgums@gmail.com, cjns@gums.ac.ir
Owned by Guilan University of Medical Sciences.
Co-published by Negah Institute for Scientific Communication.
Contact Information
Caspian Journal of Neurological Sciences
Guilan University of Medical Sciences
University Tel : +9813 3333 0939
E-mail: cjnsgums@gmail.com, cjns@gums.ac.ir
